Analysts at JPMorgan Chase started coverage on shares of DaVita (NYSE: DVA)
The analysts wrote, ?By combining the steady growth and cash generation of the company?s core dialysis business with the best physician practice management asset in the country, HealthCare Partners (HCP), CEO Kent Thiry has positioned DVA at the forefront of a potentially long-term shift in healthcare delivery and reimbursement heading into reform implementation. The capability of properly incentivized, sophisticated primary care physicians to lower system costs is unquestioned, leaving only the pace and magnitude of opportunity to be decided going forward, with DVA perhaps best positioned of all to benefit.? A number of other analysts have also recently weighed in on DVA. Analysts at Nomura upgraded shares of DaVita from a ?neutral? rating to a ?buy? rating in a research note to investors on Friday, December 14th. They now have a $121.00 price target on the stock. Finally, analysts at Zacks upgraded shares of DaVita from a ?neutral? rating to an ?outperform? rating in a research note to investors on Friday, November 16th. They now have a $135.00 price target on the stock. DaVita traded up 1.60% on Thursday, hitting $112.64. DaVita has a 1-year low of $75.11 and a 1-year high of $116.50. The company has a market cap of $10.746 billion and a price-to-earnings ratio of 20.12.
DaVita last released its earnings data on Tuesday, October 30th. The company reported $1.56 earnings per share for the quarter, beating the analysts? consensus estimate of $1.55 by $0.01. DaVita?s revenue was up 11.7% compared to the same quarter last year. Analysts expect that DaVita will post $6.17 EPS for the current fiscal year.
DaVita Inc. is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD).